<DOC>
	<DOC>NCT00420537</DOC>
	<brief_summary>The purpose of this study is to verify if the combination of Everolimus with a very low dose of cyclosporine is more effective than the combination of mycophenolate mofetil with low-dose of cyclosporine in reducing the progression of kidney dysfunction in patients with heart transplantation.</brief_summary>
	<brief_title>Shift to Everolimus (RAD) Kidney Sparing Study</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Heart Transplant with 1 to 4 years of followup GFR between 20 and 60 ml/min (calculated with ColkoroftGault formula) Acute rejection in the previous 6 months Contraindications to statin therapy Ongoing infection Ongoing heart failure Myocardial infarction or myocardial revascularization after transplant Malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Kidney</keyword>
	<keyword>Heart Transplantation</keyword>
	<keyword>Creatinine</keyword>
	<keyword>Glomerular Filtration Rate</keyword>
</DOC>